peptide-information

Phrases like “American made” or “USA-synthesized” are common shorthand for research-peptide quality, but the property that actually determines whether a vial behaves reproducibly in the laboratory is documented analytical characterization — not geography. This article examines what manufacturing provenance does and does not tell a researcher, how synthetic peptides are made, where impurities arise, and what the published literature reports about substandard products in the unregulated online supply.

Why manufacturing provenance became a research question

Small molecules and antibodies dominated pharmaceutical development for decades, but advances in synthetic chemistry and biology have driven a rapid diversification of drug modalities. In 2023 the U.S. Food and Drug Administration approved a notably high number of oligonucleotide and peptide products, which together accounted for roughly 16% of all approvals that year.¹ As peptides move from niche reagents toward mainstream therapeutic and research interest, the analytical expectations placed on the raw material have risen in parallel.

For a laboratory, the practical concern is reproducibility. A peptide that is nominally identical between two lots but differs in impurity profile, counterion load, or net peptide content can shift the apparent potency of an experiment, confound dose–response work, or introduce artifacts that have nothing to do with the sequence under study. This is where the marketing language of “American made” enters the conversation: it is used as a proxy for tighter process control. The honest position, supported by the analytical literature, is that geography correlates with oversight but does not by itself certify quality — the certifying evidence is the characterization data that accompanies each batch.⁶

How research peptides are made — and where impurities arise

The overwhelming majority of research peptides are assembled by solid-phase peptide synthesis (SPPS), in which the growing chain is anchored to an insoluble resin and amino acids are added one coupling cycle at a time, most commonly using 9-fluorenylmethoxycarbonyl (Fmoc) chemistry. Each cycle involves deprotection, coupling, and washing; after the full sequence is assembled the peptide is cleaved from the resin and its side-chain protecting groups are removed, typically under strongly acidic conditions in the presence of scavengers.

Every one of those steps is a potential source of a sequence-related impurity. Incomplete coupling leaves a residue out, producing a deletion peptide; premature chain termination yields a truncation product; incomplete deprotection can leave protecting groups attached; and susceptible residues such as methionine, cysteine and tryptophan can oxidize. A systematic review of the characterization of synthetic peptide therapeutics catalogues how these impurities originate from the starting materials, the manufacturing process itself, and subsequent storage conditions, and why mass spectrometry has become central to resolving them.²

Reagent and resin quality drive the impurity floor

A frequently underappreciated point is that the quality of the consumables sets a floor on achievable purity. Work on amide-generating resin linkers showed that the quality of commercial (4-methyl)benzhydrylamine resin is not consistent, and that residual ketone or aldehyde functionalities in the resin lead directly to acylation-resistant deletion peptides during SPPS.³ In other words, a poorly characterized resin can silently seed deletion impurities before the first amino acid is even coupled — a defect no amount of downstream purification fully repairs.

Cleavage chemistry contributes its own liabilities. Investigators documented a substantial alkylation by-product when the common scavenger 3,6-dioxa-1,8-octanedithiol (DODT) was used during acidic release of methionine-containing peptides; adjusting the cleavage conditions eliminated the adduct.⁴ Such findings illustrate why manufacturing know-how — reagent selection, scavenger choice, cleavage optimization — is not a formality but a determinant of what ends up in the vial.

The analytical toolkit that defines purity

Because the sequence-related impurities above are structurally close to the target, they cannot be assumed away; they must be measured. Contemporary practice relies on orthogonal analytics rather than any single number. Reversed-phase high-performance liquid chromatography (RP-HPLC) separates species by hydrophobicity and provides the familiar “area-percent purity” figure, while liquid chromatography–mass spectrometry assigns identity and resolves co-eluting impurities that a UV trace alone would miss.²

For more complex targets the field has moved toward tiered strategies. A method-development framework for macrocyclic peptides in drug discovery described layering complementary separations and detection modes to characterize materials that can present multiple isomers and variable charge states, precisely because no established single standard exists for such molecules.⁵ Underpinning all of this is the role of well-characterized reference standards: a review from a national standards laboratory detailed how peptide reference standards are produced and value-assigned using NMR, mass spectrometry and chromatography to anchor identity, purity and strength determinations.⁶ Without a trustworthy standard, a purity percentage is a number without a fixed meaning.

What “purity” on a label actually means

A single “98% pure” claim compresses several distinct quantities, and conflating them is a common source of confusion. Chromatographic purity (HPLC area-percent) describes how much of the detected peptide-related signal corresponds to the target sequence. It says nothing directly about how much of the vial’s mass is peptide at all.

Net peptide content is a separate figure: lyophilized peptides routinely carry bound water and residual counterions — commonly trifluoroacetate (TFA) left over from HPLC purification — so a milligram of powder is not a milligram of peptide. The characterization literature emphasizes that impurities and associated species arising from the manufacturing and purification process must be accounted for when a material’s strength is assigned, which is exactly why reference-standard-anchored value assignment matters.⁶ For a researcher preparing reconstitution calculations, the practical consequence is that chromatographic purity and net peptide content are both needed to know what is actually being weighed out; either alone can mislead.

This is also why a Certificate of Analysis (CoA) that reports HPLC purity and mass-spectrometric identity for the specific lot is more informative than any origin label. It ties a number to a measurement performed on the material in hand.²

Contamination beyond the sequence

Purity in the chromatographic sense is necessary but not sufficient, because contaminants that are not peptide-related do not appear on a peptide HPLC trace. Chief among these is bacterial endotoxin (lipopolysaccharide). In protein and peptide preparations produced with any biological step, endotoxin can be present at levels that perturb cell-based assays even when the target material looks chromatographically clean; procedures developed specifically to yield endotoxin-free protein preparations exist precisely because of this problem.¹⁰

Detecting such contamination requires dedicated assays rather than sequence analytics. Innate-immune signalling is exquisitely sensitive to microbial molecules, and reporter systems built on NF-κB activation have been used to detect microbial contaminants in biological samples and protein preparations at low levels.¹¹ The general lesson for laboratory sourcing is that a complete quality picture spans two axes: sequence fidelity (HPLC/MS) and freedom from external contaminants (endotoxin and bioburden testing). A supplier that documents only the first has characterized only half of the material.

The documented problem of substandard products

The concern that motivates “made in the USA” language is not hypothetical. Substandard and falsified medicines are a recognized global public-health problem, and post-market surveillance studies have quantified both their prevalence and the cost of detecting them.⁸ Systematic review of online pharmacies has repeatedly flagged issues with the quality of drugs sold electronically and the legitimacy of the sellers themselves.⁹

The peptide space has its own direct evidence. A multifactor market-surveillance study purchased semaglutide products sold online without a prescription and evaluated their quality and safety, situating the findings within concerns about substandard and falsified products entering an unregulated supply chain driven by surging demand.⁷ For research procurement, the take-away is not that any particular seller is compromised, but that an unregulated grey market demonstrably contains products whose contents do not match their labels — and that documentation, not branding, is what distinguishes a characterized material from an uncharacterized one. Where a laboratory works with GLP-1 research peptides such as semaglutide or tirzepatide, lot-level analytical records are the relevant safeguard.

Provenance as a proxy: what it does and does not guarantee

Domestic manufacturing is best understood as a proxy variable. It tends to correlate with a regulatory and quality-system environment that makes rigorous process control more likely: consistent reagent sourcing, validated cleavage and purification steps, and routine analytical release testing of the kind described throughout this article. In that sense, provenance can meaningfully shift the prior probability that a given lot is well characterized.

What provenance cannot do is replace the measurement. A peptide made anywhere is only as good as the deletion-peptide floor set by its resin,³ the by-products avoided during cleavage,⁴ and the orthogonal analytics run on the finished lot.⁵ The defensible sourcing standard, therefore, is not a flag on the label but a specific, verifiable evidence trail: a lot-specific CoA reporting HPLC area-percent purity and mass-spectrometric identity, a stated net peptide content, and, where the intended assay is contamination-sensitive, endotoxin data. Provenance is a reasonable first filter; characterization is the decision.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.